Tomita A, Fuchino Y, Otsuka K, Shinohara T, Tanaka S N, Umeno T, Ikeda S
Department of Surgery 1, School of Medicine, Fukuoka University, Japan.
Anticancer Res. 1998 Sep-Oct;18(5D):3937-9.
We performed endogenous/exogenous TNF (EET) therapy using, as a primer, recombinant TNF-SAM2 (rTNF-S) as a premier; it has a broader anti-cancer spectrum and is less toxic than conventional TNF, and OK-432 as a trigger in patients with metastasis of colorectal cancer to the lung and/or liver.
The subjects consisted of 34 patients of whom 8 had lung metastasis, 17 liver metastasis, and 9 lung and liver metastasis. EET therapy was performed without chemotherapy in 11 patients and with anti-cancer drugs such as mitomycin-C (MMC) and 5-FU in the other 23.
No patients showed a complete response. Partial response was observed in 10 patients (29.4%), minor response in 8 (23.5%), no change in 14 (41.2%), and progressive disease in 2 (5.8%). The response rate was 29.4%. A greater effect was observed in patients treated with EET in combination with anti-cancer drugs than those treated with EET alone. No serious side effects were observed, although all patients developed a fever above 38 degrees C, chill, and shiver.
EET therapy with rTNF-S combined with anti cancer drugs chemotherapy may be effective, and further studies are needed to select the most suitable anticancer drugs for combination with, and to determine the effective frequency of treatment.
我们采用重组肿瘤坏死因子 - SAM2（rTNF - S）作为起始剂，OK - 432作为触发剂，对结直肠癌肺和/或肝转移患者进行内源性/外源性肿瘤坏死因子（EET）治疗。rTNF - S比传统肿瘤坏死因子具有更广泛的抗癌谱且毒性更低。
研究对象包括34例患者，其中8例有肺转移，17例有肝转移，9例有肺和肝转移。11例患者在未进行化疗的情况下接受EET治疗，另外23例患者在接受EET治疗的同时联合使用丝裂霉素 - C（MMC）和5 - 氟尿嘧啶（5 - FU）等抗癌药物。
无患者出现完全缓解。10例患者（29.4%）出现部分缓解，8例（23.5%）出现轻度缓解，14例（41.2%）病情无变化，2例（5.8%）病情进展。缓解率为29.4%。与单独接受EET治疗的患者相比，联合抗癌药物接受EET治疗的患者效果更佳。尽管所有患者均出现体温高于38摄氏度、寒战和发抖，但未观察到严重副作用。
rTNF - S联合抗癌药物化疗的EET治疗可能有效，需要进一步研究以选择最适合联合使用的抗癌药物，并确定有效的治疗频率。
